326-69-2

Basic information

• Product Name: 2-bromo-1-ethoxy-4-fluorobenzene
• Synonyms: 2-bromo-1-ethoxy-4-fluorobenzene;2-BROMO-4-FLUOROPHENYL ETHYL ETHER
• CAS NO: 326-69-2
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.052
• Mol File: 326-69-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 232.228°C at 760 mmHg
• Flash Point: 113.207°C
• Appearance: /
• Density: 1.457g/cm³
• Vapor Pressure: 0.091mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-bromo-1-ethoxy-4-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-ethoxy-4-fluorobenzene(326-69-2)
• EPA Substance Registry System: 2-bromo-1-ethoxy-4-fluorobenzene(326-69-2)

Safety Data

• Hazardous Substances Data: 326-69-2(Hazardous Substances Data)

Usage

General Description

2-bromo-1-ethoxy-4-fluorobenzene is a chemical compound with the molecular formula C8H8BrFO. It is a colorless to pale yellow liquid that is primarily used as an intermediate in the production of various pharmaceuticals, agrochemicals, and other organic compounds. It is a halogenated aromatic compound that contains bromine, ethoxy, and fluorine functional groups, and is known for its strong, sweet, and aromatic odor. 2-bromo-1-ethoxy-4-fluorobenzene is commonly used in organic synthesis and chemical research, and as a building block in the creation of various complex organic molecules. It is important to handle this chemical with caution, as it is flammable and may cause irritation to the skin, eyes, and respiratory system if not properly handled.

InChI:InChI=1/C8H8BrFO/c1-2-11-8-4-3-6(10)5-7(8)9/h3-5H,2H2,1H3

Upstream product

• 496-69-5 2-bromo-4-fluoro-phenol 
• 75-03-6 ethyl iodide 
• 56-23-5 tetrachloromethane 
• 459-26-7 4-ethoxy-1-fluorobenzene 
• 7726-95-6 bromine 
• 74-96-4 ethyl bromide 

Downstream Products

• 1299312-95-0 4-chloro-2-({2-ethoxy-5-fluorophenyl}carbonyl)aniline 

Relevant articles and documents

Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase

The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new antitubercular drugs. Protein synthesis inhibitors have played an important role in

2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA

The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)- The values and preferred values of the variables in Structural Formula I are defined herein.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.